Long-Term Risks of Montelukast

Introduction to Risks

• The FDA issued a black box warning in 2020 regarding serious neuropsychiatric events associated with montelukast, including suicidal thoughts and actions, depression, anxiety, sleep disturbances, and behavioral changes, which should be carefully weighed against benefits, particularly in patients with mild disease that can be adequately treated with alternative medications 1, 2

Clinical Context and Risk-Benefit Considerations

• The FDA explicitly states that the benefits of montelukast may not outweigh the risks, especially when disease symptoms are mild and can be adequately treated with other medications 1
• Montelukast is less effective than intranasal corticosteroids for allergic rhinitis and should not be considered first-line therapy when intranasal steroids are appropriate 3

Monitoring and Patient Counseling

• Monitor for unusual behavioral or mood changes when starting montelukast, particularly in the first weeks of therapy 2, 4
• Explicitly discuss neuropsychiatric risks before initiating therapy, including the potential for suicidal thoughts and behavioral changes 1, 2

Common Pitfalls to Avoid

• Do not prescribe montelukast for mild disease when safer alternatives like intranasal corticosteroids are available and appropriate 1, 3
• Do not continue therapy without reassessing risk-benefit if any neuropsychiatric symptoms emerge, even if mild 1

Adverse Effects of Montelukast

Common Adverse Effects

• The American Academy of Allergy, Asthma, and Immunology notes that headache is a common side effect of montelukast 5
• Hepatitis and elevated liver enzymes are less common but important adverse effects of montelukast 5

Rare but Serious Adverse Effects

• The American Academy of Allergy, Asthma, and Immunology reports that eosinophilia is a rare but serious adverse effect of montelukast, with a causal association with Churg-Strauss syndrome not definitively established 6

Special Populations

• The American College of Obstetricians and Gynecologists notes that montelukast is Pregnancy Category B and may be used during pregnancy when there has been a uniquely favorable prepregnancy response 7

Critical Clinical Pitfalls to Avoid

• The American Academy of Allergy, Asthma, and Immunology recommends that montelukast not be prescribed for mild disease when safer alternatives like intranasal corticosteroids are available and appropriate, as montelukast is less effective than intranasal corticosteroids for allergic rhinitis 6

Montelukast Adverse Events and Risk-Benefit Considerations

Rare but Serious Adverse Events

• Pancreatitis has been reported in clinical trials, although causality has not been established, in patients taking montelukast 8

Critical Risk-Benefit Considerations

• The EPOS2020 steering group does not advise adding montelukast to nasal corticosteroids due to lack of demonstrated benefit, for patients with allergic rhinitis 9